Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes-Reference-Cited by-同舟云学术

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Published:2019-08-26 Issue:11 Volume:21 Page:2564-2569
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bailey Clifford J.¹^ORCID,Del Prato Stefano²^ORCID,Wei Cheryl³,Reyner Daniel³,Saraiva Gabriela³

Affiliation:

1. School of Life and Health SciencesAston University Birmingham UK

2. Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental MedicineUniversity of Pisa Pisa Italy

3. AstraZeneca, R&D Bio Pharmaceuticals, Late CVRM Gaithersburg Maryland

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13841

Reference16 articles.

1. Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin

2. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

3. Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

4. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

5. Dapagliflozin add‐on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled 102‐week trial;Bailey CJ;BMC Med,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes;Science Translational Medicine;2023-02

2. On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide;Journal of Controlled Release;2022-12

3. Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study;Frontiers in Endocrinology;2022-10-31

4. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors;International Journal of Molecular Sciences;2022-03-26

5. Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea;2022-03-26